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Study Design
Study Design
Single Arm, Prospective, EU, Multicenter, Safety and 
Effectiveness Study
Objective
To investigate the safety, clinical use, and outcomes of the 
Lutonix Drug Coated Balloon for treatment of Long Lesions 
(≥ 14 cm) in the femoropopliteal artery
Number of 
patients/sites
118 DCB patients – 14 sites
Key Inclusion Criteria
Rutherford Class: 2-4, TASC II Class C or D Lesions, ≥ 70% 
stenosis lesion, lesion length ≥ 14 cm, vessel diameter of
4-7 mm
Key Exclusion Criteria
Life expectancy < 1 yr., prior vascular surgery of the index 
limb, target lesion previously stented, inadequate distal 
outflow (> 50% stenosis of distal popliteal or all three tibial
vessels)
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Baseline Angiogram
Treatment Device
Dilatation with Lutonix Drug 
Coated Balloon
Defined Pre-Dilatation
(Balloon inflated to ~1mm 
<RVD)/Enrollment
Bailout stenting if required
Recruitment
Single-Arm Study - Levant 2 Design
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Inclusion/Exclusion Criteria √ √
Informed Consent √
Medical History √
Physical Exam √ √ √ √ √ √ √
Medication Compliance √ √ √ √ √ √ √
Resting ABI √ √ √ √ √ √ √
Rutherford Classification √ √ √ √ √
WIQ & EQ5D Questionnaires √ √ √ √
Angiogram √ √
Adverse Event Monitoring √ √ √ √ √ √ √ √
Duplex Ultrasound √ √ √ √
AEs CEC Adjudicated
Patient Follow-Up
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Description
Lutonix Long Lesion Study
DCB Subjects
Age (Years), Mean ± SD (n) 67.6 ± 9.23 (118) 
BMI >30 kg/m2 (n/N) 26.3 % (30/114)
Diabetes 36.4% (43/118)
Baseline Target Limb Rutherford Grade, % (n/N) 
2 
3 
4 
24.1% (28/116) 
69.0% (80/116) 
5.2% (6/116) 
Baseline ABI of Target Limb, Mean ± SD (n) 0.69 ± 0.26 (111)
Highest TASC Classification, % (n/N) 
B
C
D
0.8% (1/118)
77.1% (91/118)
22.0% (26/118)
Total Target Lesion Length (mm), Mean ± SD (n) 212.5 ± 68.32 (117)
Maximum Lesion Length (mm) 450mm
Balloons per Subject, Mean ± SD (n) / Range 2.2 ± 0.62 (118) / (1.0, 4.0) 
CTO, % (n/N)  52.1% (61/117)  
RVD (mm), Mean ± SD (n) 4.7 ± 0.76 (117) 
Calcification, % (n/N)  88.1% (104/118)  
Severe Calcification 21.2% (22/104)
Demographics / Procedural Information
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Freedom from Primary Safety Events*
Time N1
Survival2
% [95% CI] 
Month 1 (30 Days)  117  99.2% [94.1%, 99.9%]  
Month 6 (183 Days)  111  94.0% [87.8%, 97.1%]  
Month 12 (365 Days)  92  82.3% [73.9%, 88.2%]  
Month 24 (730 Days)  72  70.5% [60.8%, 78.2%]  
¹Subjects ongoing without an event at the beginning of the visit window
²Primary safety response estimate based on Kaplan-Meier estimate
*Composite of freedom from all-cause peri-procedural (≤30 day) death and freedom at 1 year from the following: index limb amputation 
(above or below the ankle) and index limb re-intervention. 
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82.3%
70.5%
Freedom From
Long Lesion Study
% (n/N) 
LEVANT 2 Study
DCB  Subjects
% (n/N) 
All Cause Death 94.5% (103/109)  92.4% (257/278)
Major Amputation 98.1% (104/106)  99.6% (260/261)
Minor Amputation 98.1% (103/105)  99.6% (259/260)
TVR 73.6% (78/106) 78.5% (208/265)
Safety Profile Comparison to Levant 2
Freedom From
Long Lesion Study
% (n/N) 
LEVANT 2 Study
DCB  Subjects
% (n/N) 
Vascular Complications
30 days
97.4% (112/115) 95.8% (295/308)
3.5x Longer Lesions with Similar Safety Profile
Low 2.6% Vascular Complications Rate
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Freedom from TLR
1 Subjects ongoing without an primary patency failure at the beginning of the visit window
2 TLR-Free response estimate based on Kaplan-Meier estimates
Time N1
Survival2
% [95% CI] 
Month 1 (30 Days)  118  100.0% [NA, NA]  
Month 6 (183 Days)  114  97.4% [92.2%, 99.2%]  
Month 12 (365 Days)  97  87.4% [79.7%, 92.4%]  
Month 24 (730 Days)  76  75.6% [66.2%, 82.7%]  
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87.4%
75.6%
Assessment From Baseline Improvement at 24m
Rutherford ~80% of Subjects Improved by at Least One Category
>60% of Subjects Improved by at Least Two Categories
ABI 35% Improvement
Clinical Benefit Improvement
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Long Lesion Study Zilver PTX
Age (Years), Mean ± SD (n) 67.6 ± 9.23 (118) 66.9 ± 9.5 (110)
Male, % (n/N) 73.7% (87/118)  74.5% (82/110)  
Hypertension% (n/N) 85.6% (102/118) 82.7% (91/110)
Hypercholesteremia% (n/N) 38.1% (45/118) 62.7% (69/110)
Any Diabetes % (n/N) 
Type 1
Type 2
36.4% (43/118)
0.8% (1/118)
35.6% (42/118)
39.1% (43/110)
9.3% (4/43)
90.7% (39/43)
Smoking % (n/N) 
Current Smoker
Past Smoker 
70.3% (83/118)
41.5% (49/118)
28.8% (34/118)
79.1% (87/110)
39.1% (43/110)
40.0% (44/110)
Renal Disease % (n/N) 27.1% (32/118) 13.6% (15/110)
Any Calcification% (n/N) 
Severe Calcification
88.1% (104/118)
21.2% (22/104)
86.2% (100/116)
17.2% (20/116)
Lutonix Long Lesion vs. Zilver PTX
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Kaplan- Meier
Freedom From
Long Lesion Study Zilver PTX
TLR
(12 months)
87.4% 75.6%
TLR
(24 months)
75.6% 71.3%
Lutonix Long Lesion vs. Zilver PTX
(Mean length 212.5+68.3mm /
Range 100.0, 450.0)
(Lesion length range >140-240mm)
Higher Freedom from TLR!
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• Complex Long Lesions:
• Lesion Lengths Up to 450mm
• 88% Calcification 
• 21% Severely Calcified
• 99.1% TASC C and D Lesions
• Similar Safety Profile to Levant 2
• Low (2.6%) Vascular Complications Rate
• Rutherford Category Improvement
• ~80% of Subjects Improved by at Least One Category
• >60% of Subjects Improved by at Least Two Categories
Conclusions
Higher Freedom From TLR than Zilver PTX
at 12 and 24 Months 
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